AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology
ABBVie today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ for the treatment …
– ABBVie (NYSE: ABBV) today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ (upadacitinib) for the
ABBVie today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs . 1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 …
ABBVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs). 1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 mg met the primary endpoint of ACR20 response at week 12 versus placebo as well as key secondary endpo
Share this article
NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ AbbVie (NYSE: ABBV) today announced that the
New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ
™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).
1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 mg met the primary endpoint of ACR20 response at week 12 versus placebo as well as key secondary endpoints.
1 These data show upadacitinib s potential to improve clinical and radiographic outcomes for people with psoriatic arthritis, a complex and progressive autoimmune disease, said Thomas Hudson, MD, senior vice president, research and development, chief scientific officer, AbbVie. Ultimately, our goal is to help more patients achieve d
Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
- 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p 0.001)[1]
- All ranked secondary endpoints were met[1]
- These results reaffirm findings from the first Phase 3 induction study, U-ACHIEVE[1,2]
- Safety results were consistent with the previous Phase 3 induction study and the known profile of upadacitinib, with no new safety risks observed[1-6]
- Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral therapy for moderate to severe ulcerative colitis and several other immune-mediated diseases[1,7-14]
Second Phase 3 Induction Study Confirms Upadacitinib ) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.